Estamos no ar no ! Saiba mais

Avid Bioservices, Inc. Common Stock

CDMO

Valor de mercado US$ 799 mi

Deslistada

CDMO foi retirado da bolsa em 4 de fevereiro de 2025.

Voltar ao ranking

Sobre: Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.

Funcionários: 371

Saúde Fabricantes de medicamentos — geral

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 0%

Neutro 0%

Negativo 0%

The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation

LOS ANGELES, CA / ACCESS Newswire / February 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

The Schall Law Firm Invites Shareholders With Losses In Avid Bioservices, Inc. To Join A Securities Fraud Investigation

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Avid Bioservices, Inc. For Securities Fraud

LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Avid Bioservices, Inc. For Securities Fraud

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / January 31, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm

Avid Stockholders Approve Transaction with GHO and Ampersand

TUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Avid stockholders voted to approve the transaction with GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”) at the Avid special meeting of stockholders (the “Special Meeting”) held earlier today.

Avid Stockholders Approve Transaction with GHO and Ampersand

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Avid Bioservices, Inc. For Securities Fraud

LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Avid Bioservices, Inc. For Securities Fraud

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud

LOS ANGELES, CA / ACCESS Newswire / January 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / January 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

Avid Bioservices, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud

LOS ANGELES, CA / ACCESS Newswire / January 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQ:CDMO) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Avid board breached its fiduciary duties to shareholders.

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Avid Bioservices, Inc. For Securities Fraud

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™